The first results from the GARFIELD-VTE (Global anticoagulant registry in the field—venous thromboembolism) were presented at the International Society on Thrombosis and Haemostasis Congress 2017 (8–13 July, Berlin, Germany) providing a contemporary picture of VTE management worldwide.
A study presented at the American Venous Forum (AVF; 14–17 February, New Orleans, USA) suggests that secondary interventions for primary iliac vein stenting are “associated with good outcomes,” with a rate of 10.2% reported.
A presentation at the American Venous Forum (AVF; 14–17 February, New Orleans, USA) has attempted to shed light on what could be an underdiagnosed cause of pelvic pain caused by pelvic venous insufficiency—iliac vein compression.
Medtronic has completed the previously announced sale of a number of its businesses to Cardinal Health, including its Deep Vein Thrombosis (compression) division. The transaction was worth US$6.1 billion.
New evidence suggests that minimally invasive methods to ablate superficial venous reflux in patients with end-stage venous insufficiency are as effective as traditional open venous stripping.
Researchers at North Carolina State University (Raleigh, USA) and the University of North Carolina at Chapel Hill (Chapel Hill, USA) have developed a new surgical tool that uses low-frequency intravascular ultrasound to break down blood clots that cause deep vein thrombosis.
Results from the OPTALYSE PE trial have been presented at the American Thoracic Society International Conference in Washington, DC, USA. The results show that pulmonary embolism (PE) can be treated effectively with EKOS (BTG) over a shorter period and at safer thrombolytic doses compared with the current treatment standard, which will allow for scheduling flexibility and efficiencies in clinician time and drug costs.
Teleflex has announced a new three-year product category contract with Vizient for non-tunnelled central venous catheters. Vizient is the largest member-driven health care performance improvement company in the USA.
The UK’s Information Commissioner’s Office (ICO) has found that the Royal Free National Health Service (NHS) Foundation Trust (London, UK) did not adhere to the UK’s Data Protection Act when it provided patient details to Google DeepMind.
The US Food and Drug Administration (FDA) has approved betrixaban (Bevyxxa, Portola), the first and only anticoagulant for hospital and extended duration prophylaxis (35 to 42 days) of venous thromboembolism (VTE) in adult patients hospitalised for an acute medical illness who are at risk for thromboembolic complications due to moderate or severe restricted mobility and other risk factors for VTE.
Guerbet has announced that the Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM; The German Federal Institute for Drugs and Medical Devices) has now approved Lipiodol Ultra-Fluid for use after intra-arterial catheterisation of the hepatic artery for the visualisation and localisation of hepatocellular carcinoma in the intermediate stage in adults.
According to our results, the physician who performs prostatic artery embolization procedures, even with a ceiling suspended shield, would reach the annual radiation limit for the left eye with just one procedure per week, writes Gustavo Andrade, Recife, Brazil.
The 2017 edition of the annual PAIRS meeting was held in Dubai 15–18 March and reflected the growing enthusiasm of the interventional radiology community in the Middle East, writes Hicham T Abada.
The 459-patient randomised controlled SARAH study shows that local treatments of advanced or inoperable hepatocellular carcinoma with selective internal radiation therapy (SIRT) did not lead to a planned superiority difference in overall survival compared to standard-of-care systemic therapy with sorafenib. However, SIRT had far fewer side-effects and patients who received this treatment had a significantly better quality of life.
Two patients were treated for hepatocellular carcinoma and one patient was treated for malignant colorectal cancer metastasised to the liver.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos